Cresco Labs (OTCMKTS:CRLBF - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01), Zacks reports. The firm had revenue of $165.76 million during the quarter, compared to the consensus estimate of $164.37 million. Cresco Labs had a negative return on equity of 16.52% and a negative net margin of 9.15%.
Cresco Labs Stock Performance
Shares of OTCMKTS:CRLBF traded down $0.06 during midday trading on Friday, hitting $0.62. The company had a trading volume of 932,635 shares, compared to its average volume of 636,426. Cresco Labs has a 12-month low of $0.52 and a 12-month high of $2.05. The company has a fifty day moving average of $0.70 and a two-hundred day moving average of $0.86. The company has a market cap of $303.45 million, a price-to-earnings ratio of -3.09 and a beta of 1.73. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39.
Analyst Ratings Changes
Separately, Cormark upgraded Cresco Labs from a "hold" rating to a "moderate buy" rating in a research note on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy".
View Our Latest Research Report on CRLBF
About Cresco Labs
(
Get Free Report)
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Further Reading
Before you consider Cresco Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.
While Cresco Labs currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
